Session Type: ACR Poster Session A
Session Time: 9:00AM-11:00AM
Background/Purpose: RA Patients with anti-citrullinated protein antibody (ACPA) or rheumatoid factor (RF) are known to have worse clinical outcomes compared to seronegative patients. To determine if there were differences in clinical, laboratory features and outcomes of RA patients based on their ACPA and RF status (group I: ACPA+RF+, II: ACPA+RF -, III: ACPA -RF+, IV: ACPA-RF-). All patients fulfilled the 1987 ACR criteria for RA.
Methods: ACPA and RF titres were analysed by ELISA. Statistical analysis was conducted using STATA 13.0 (College Station, TX). We used Chi-square test or Fisher’s exact test to compare categorical variables. We used ANOVA or Kruskal Wallis test for continuous variables, followed by posthoc Tukey’s HSD test when appropriate. A two tailed significance level of 0.05 was chosen for all tests.
Results: The study population comprises 970 patients (group I 663, II 68, III 106, IV 133) with mean disease duration of 174.4
Conclusion: ACPA+RF+ RA patients have higher baseline ESR and fewer achieve remission, despite higher use of synthetic DMARDs compared to ACPA-RF+ and ACPA-RF- patients. However, these differences did not affect their functional status or quality of life.
To cite this abstract in AMA style:Koh ET, Chan AM, See WQ, Xiang W, Leong KP. Impact of Anti-Citrullinated Protein Antibody and/or Rheumatoid Factor on Rheumatoid Arthritis Manifestations and Outcomes [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/impact-of-anti-citrullinated-protein-antibody-andor-rheumatoid-factor-on-rheumatoid-arthritis-manifestations-and-outcomes/. Accessed December 5, 2020.
« Back to 2016 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/impact-of-anti-citrullinated-protein-antibody-andor-rheumatoid-factor-on-rheumatoid-arthritis-manifestations-and-outcomes/